CMN 548 – ADVANCED PSYCHOPHARMACOLOGY & NEUROBIOLOGY EXAM WITH QUESTION AND EXPLAINED ANSWERS/JUST RELEASED 2026

1


CMN 548 – ADVANCED PSYCHOPHARMACOLOGY &
NEUROBIOLOGY EXAM WITH QUESTION AND
EXPLAINED ANSWERS/JUST RELEASED 2026
INSTANT FREE PDF


Thisexamtestsadvancedunderstandingofpsychopharmacologyandneurobiologyinclinicalsettin gs
qw qw nc cn




.Keyareasinclude:
n
c n
c




1. Neurotransmitters& Receptors qw




o Majorneurotransmitters(dopamine,serotonin,GABA,glutamate).

o Receptortypes(ionotropicvs.metabotropic,agonistsvs.antagonists).

2. Pharmacokinetics&Pharmacodynamics

o Absorption,distribution,metabolism,excretion(ADME).

o Dose-response curves, half-life, potency, efficacy.
cn cn cn cn




3. Psychotropic Medications
cn




o Antidepressants, antipsychotics, mood stabilizers, anxiolytics.
cn cn cn cn




o Mechanisms,indications,sideeffects,andinteractions.

4. NeurobiologyofMentalDisorders

o Biologicalbasesofdepression,anxiety,schizophrenia,bipolardisorder.

o Brainregionsinvolved(prefrontalcortex,amygdala,hippocampus).

5. ClinicalApplications

o Choosingmedicationsbasedonsymptomprofiles.
qw qw




o Monitoringtherapeuticresponseandadverseeffects.
qw qw




Tip:Focusonmechanismsofaction,receptorinteractions,neurotransmitterpathways,andclinicalco n
c n
c cn




nsiderations.

,2




1. Whichneurotransmitterisprimarilyimplicatedinthepa cn




thophysiologyofschizophrenia?
A. Dopamine
B. Serotonin
C. GABA
D. Acetylcholine
Answer:A Rationale:Dopaminedysregulation,particularlyhyperactivityint
cn




hemesoli mbicpathway,iscentraltoschizophrenia.
cn




2. SSRIsprimarilyincreasethesynapticavailabilityofwhichne
qw cn




urotransmitter?
A. Serotonin
B. Dopamine
C. Norepinephrine
D. GABA
Answer:A Rationale:SSRIsblockserotoninreuptake,increasingserotonergicac
cn




tivityi nthesynapse.
cn

,3


3. Whichreceptortypeisionotropic?
A. NMDA
B. G-proteincoupledserotoninreceptor(5-HT1A)
C. DopamineD2receptor
D. Alpha-2adrenergicreceptor
Answer:A Rationale:Ionotropicreceptors(e.g.,NMDA)arel
cn qw




igand-
gatedionchannelsthatmediatefastsynaptictransmission.


4. Thehalf-lifeofadrugrefersto:
qw




A. Thetimeittakesforplasmaconcentrationtodecreaseby50%
B. Thetimetoreachpeakeffect
C. Thetimeuntilthedrugiscompletelyexcreted
qw




D. Thedurationoftherapeuticeffect
Answer:A Rati
cn




onale:Half-
lifemeasuresthetimeneededfordrugplasmalevelstofallbyhalf.


5. Benzodiazepinesexerttheireffectby:
A. EnhancingGABA-A receptoractivity
qw




B. Blockingdopaminereceptors
C. Inhibitingserotoninreuptake
qw




D. ActivatingNMDA receptors
qw




Answer:A Rationale:Benzodiazepinespotentia
cn




teGABA-
mediatedchlorideinflux,causingCNSinhibition.

, 4




6. Lithium’stherapeuticeffectinbipolardisorderisprimarilythrough:
qw




A. Modulationofintracellularsignaling andneurotransmitterbalance
qw




B. DopamineD2receptorblockade
C. GABA-A receptorenhancement
qw




D. Serotoninreuptakeinhibition
Answer:A Rationale:Lithiummodulatessecondmessengersystemsandstabi
cn




lizesneu ronalsignaling.
cn




7. Clozapineisclassifiedasa:
A. Atypicalantipsychotic
B. Typicalantipsychotic
C. SSRI
D. Moodstabilizer
Answer:A Rationale:Clozapineisanatypicalantipsychoticwithhigheffica
cn




cyfortrea tment-resistantschizophrenia.
cn




8. WhichneurotransmitterisprimarilyinhibitoryintheCNS?
A. GABA
B. Glutamate
C. Dopamine
D. Acetylcholine